Mirus Bio LLC and Reinnervate Limited Collaborate to Introduce the 3D Transfection System: Enabling Transfection of Cells in 3D Culture
Published: Nov 16, 2011
MADISON, Wis., Nov. 16, 2011 /PRNewswire/ -- Ideal for transfecting cells propagated in 3D cell culture, the new 3D Transfection System combines the technologies of Reinnervate's alvetex® 3D cell culture plates and Mirus Bio's TransIT®-3D Transfection Reagent, enabling scientists to conduct research that more accurately mimics the tissue environment.
Under the agreement, Mirus will produce and sell the 3D Transfection System which contains the TransIT®-3D Transfection Reagent, alvetex® 3D cell culture plates and provide detailed protocols for transfecting cell lines maintained in 3D cell culture.
"Cell based research is actively moving towards cellular models, such as 3D cell culture, that more accurately represent intact tissue," said Scott Hayes, Vice President of Scientific Operations at Mirus Bio, LLC. "With the introduction of the TransIT®-3D Transfection Reagent, Mirus addresses an unmet need for efficient delivery of nucleic acids to cells established and propagated in a 3D cell culture environment. By combining the TransIT®-3D Transfection Reagent with the innovative scaffold structure of alvetex® plates from Reinnervate, researchers will have access to a cell culture model that is more biologically relevant than routine 2D culture and amenable to easy and high-efficiency transfection."
"Scientists are increasingly looking for in vitro cell-based assay that better mimic and predict complex biological processes," commented Richard Rowling, Commercial Director at Reinnervate. "We believe the 3D Transfection System will be of broad appeal for cell biologists seeking to improve their research capabilities beyond the limitations of mono-layer culture. We are delighted to be collaborating with Mirus to help make 3D cell culture a more routine laboratory technique."
About Mirus Bio LLC
The Transfection Experts. More than 15 years of gene delivery expertise.
The TransIT®-3D Transfection Reagent complements Mirus Bio's transfection offerings which include TransIT®-LT1 Broad Spectrum Transfection Reagent, TransIT-TKO® siRNA Transfection Reagent and a multi-platform, non-chemical alternative: Ingenio® Electroporation Kits. Mirus pioneered scientific breakthroughs in non-viral gene delivery. These advances established our products as industry leading transfection reagents. At Mirus, we continue to expand on our expertise in nucleic acid delivery research and products to better serve you.
Reinnervate is an innovative life sciences company dedicated to making routine 3D cell culture a reality for researchers in academia and in the pharmaceutical and related industries. Reinnervate's core technology is alvetex®, a unique and proprietary scaffold that enables routine 3D cell culture in the laboratory. Alvetex® provides a nanoscale environment that supports genuine homogeneous 3D cell growth. Reinnervate continues to develop its technology for use in the 3D cell culture. During 2012 Reinnervate will deliver further innovative products to help researchers improve the growth and function of their cultured cells.
Reinnervate was founded in 2002 based on the pioneering research of Professor Stefan Przyborski and his lab at Durham University, UK, and is funded by NorthStar Equity Investors (NSEI), management and private investors.
SOURCE Mirus Bio LLC